A novel hydrocortisone-ethanol gel ointment for treating atopic dermatitis (eczema) in children: A double blind, randomized, controlled clinical trial
Main Article Content
Keywords
atopic dermatiits, treatment, topical treatment
Abstract
Importance: Current treatments for moderate to severe atopic dermatitis (AD) in children are limited by incomplete efficacy, long time to benefit, and parental concerns about safety. This study evaluated a novel ointment for treating AD containing 0.83% hydrocortisone and 17% dispersed ethanol gel micro bubbles.
Observations:20 children with moderate to severe AD participated in a one-week double blind, randomized, and controlled clinical trial. They were randomly assigned to apply BID either an ointment with 1% hydrocortisone ointment (HC) or a novel ointment containing 1% hydrocortisone and dispersed ethanol gel droplets (HC-EG).
The primary endpoint was superiority of HC-EG over HC ointment in SCORAD score improvement during therapy. A secondary endpoint was improvement in pruritus score during therapy. Both the primary and secondary endpoints were reached in this study. SCORAD score improved 74% on average with HC-EG ointment vs 41% with HC ointment (p=.02). Pruritus score improved 68% on average with HC-EG ointment vs 37% with HC ointment (p=.009). No toxicity requiring stopping therapy was observed in either treatment group.
Conclusions and Relevance: Inthis small controlled study HC-EG ointment was superior to HC ointment both in improving visible rash and pruritus of AD. Parents felt HC-EG ointment was safe because it contains no prescription corticosteroids, prescription immunosuppressants, or antibiotics. Independent larger studies would be a next step in evaluating further this new way to treat AD.
References
Silverberg JI and Greenland P, “Eczema and cardiovascular risk factors in 2 US adult population studies “, Journal of Allergy and Clinical Immunology, 2015(135) 3, Pages 721-728.
National Institute for Health and Care Excellence, “Atopic eczema in children: Management of atopic eczema in children from birth up to the age of 12 years”, www.nice.org.uk/nicemedia/pdf/CG057FullGuideline.pdf (accessed2009 March 15)
Vernon HJ, Lane AT, and Weston W, “ Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis”, JAAD 1991;24:603-7.
Huang JT, Abrams M, Tlougan B, et al, Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity, Pediatrics 2009;123;e808.
Kojima R1, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, Ohya Y, Saito H, Matsumoto K, Factors associated with steroid phobia in caregivers of children with atopic dermatitis, Pediatr Dermatol. 2013 Jan-Feb;30(1):29-35.
Simpson EL, Basco M, Hanifin J, A cross-sectional survey of complementary and alternative medicine use in patients with atopic dermatitis, Am J Contact Dermat. 2003 Sep;14(3):144-7.
Cho S-H, Strickland I, Boguniewicz M, et al. Fibronectin and fibrinogen contributes to the enhanced binding of S. aureus to atopic skin. J Allergy Clin Immunol 2001;108:269–74.
Zollner TM, Wichelhaus TA, Hartung A, Von Mallinckrodt C, Wagner TO, Brade V, et al. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy 2000;30: 994-1000.
Jennifer TH, Melissa A, Brook T, Rademaker, and Paller AS, “Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity” Pediatrics. 2009 May;123 (5):2008-2217.
,
Hall TS, Wren MW, Jeanes A, and Gant VA, “A comparison of the antibacterial efficacy and cytotoxicity to cultured human skin cells of 7 commercial hand rubs and Xgel, a new copper-based biocidal hand rub”, Am J Infect Control. 2009 May;37(4):322-6. doi: 10.1016/j.ajic.2008.09.011. Epub 2008 Dec 31.
US Department of health and Human Services, Household products database, http://householdproducts.nlm.nih.gov/cgi-bin/household/brands?tbl=brands&id=7005062 accessed 09/05/2015.
Liu P, Kurihara-Bergstrom T, Good, Cotransport of estradiol and ethanol through human skin in vitro: understanding the permeant/enhancer flux relationship, WRPharm Res. 1991 Jul;8(7):938-44.
Hon KL1, Kam WY, Leung TF, Lam MC, Wong KY, Lee KC, Luk NM, Fok TF, Ng PC, Steroid fears in children with eczema. Acta Paediatr. 2006 Nov;95(11):1451-5.
Kojima R1, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, Ohya Y, Saito H, Matsumoto K, Factors associated with steroid phobia in caregivers of children with atopic dermatitis, Pediatr Dermatol. 2013 Jan-Feb;30(1):29-35.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.